Endo Continues To Expand Generics Business With Par Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.
You may also be interested in...
Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline
With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.
Par Acquisition By TPG Allows Competing Marriage Proposals
Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.